1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 30, 59, 7, 47 and 22 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 5, 3, 1 and 6 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Kidney Cancer (Renal Cell Cancer) - Overview
- Kidney Cancer (Renal Cell Cancer) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- ssessment by Route of Administration
- Assessment by Molecule Type
- Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
- Kidney Cancer (Renal Cell Cancer) - Drug Profiles
- Kidney Cancer (Renal Cell Cancer) - Dormant Projects
- Kidney Cancer (Renal Cell Cancer) - Discontinued Products
- Kidney Cancer (Renal Cell Cancer) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Kidney Cancer (Renal Cell Cancer) - Dormant Projects, 2022
- Kidney Cancer (Renal Cell Cancer) - Discontinued Products, 2022
- Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- 4SC AG
- A28 Therapeutics Inc
- AbbVie Inc
- Actuate Therapeutics Inc
- Adicet Bio Inc
- Affimed GmbH
- Agenus Inc
- Alligator Bioscience AB
- Almac Discovery Ltd
- Alpha-1 Biologics Corp
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Anaveon AG
- AntiCancer Inc
- Apcure SAS
- Apollomics Inc
- Aravive Inc
- Astellas Pharma Inc
- AvenCell Europe GmbH
- Avesthagen Ltd
- Bavarian Nordic AS
- Bayer AG
- Beijing Foreland Pharma Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- BeyondSpring Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioNTech SE
- Biosion Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calviri Inc
- CanBas Co Ltd
- Canget BioTekpharma LLC
- Celldex Therapeutics Inc
- Centurion BioPharma Corp
- Chongqing Precision Biotech Co Ltd
- Clonz Biotech Pvt Ltd
- COARE Biotechnology Inc
- Coherent Biopharma
- Corvus Pharmaceuticals Inc
- Cothera Bioscience Pty Ltd
- CSPC Pharmaceutical Group Ltd
- CureLab Oncology Inc
- CytomX Therapeutics Inc
- Deciphera Pharmaceuticals Inc
- Deka Biosciences Inc
- DNAtrix Inc
- Duet Therapeutics Inc
- Dyadic International Inc
- Elevation Oncology Inc
- Enara Bio Ltd
- Exelixis Inc
- Fannin Innovation Studio
- Faron Pharmaceuticals Oy
- Gilead Sciences Inc
- Glycotope GmbH
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- Handa Pharmaceuticals LLC
- Helixmith Co Ltd
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- Imugene Ltd
- Incyte Corp
- Inmune Bio Inc
- Innovative Cellular Therapeutics Co Ltd
- IO Biotech Inc
- iOmx Therapeutics AG
- Jiangxi Jemincare Group Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Kind Pharmaceuticals
- Komipharm International Co Ltd
- Lantern Pharma Inc
- Luye Pharma Group Ltd
- MacroGenics Inc
- Marino Biotechnology Co Ltd
- MaxiVAX SA
- MdBioLab
- MedAnnex Ltd
- Merck & Co Inc
- Merck KGaA
- Metagone Biotech Inc
- Metis Precision Medicine
- MicuRx Pharmaceuticals Inc
- Midissia Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Mina Therapeutics Ltd
- Mirati Therapeutics Inc
- Moleculin Biotech Inc
- Multitude therapeutics Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- NanoVation Therapeutics Inc
- NeuClone Pty Ltd
- Novartis AG
- Oncolys BioPharma Inc
- Oncovir Inc
- OneThree Biotech Inc
- Orion Corp
- Orpheus Therapeutics Inc
- Panorama Researchama Research
- Pfizer Inc
- PharmaTher Holdings Ltd
- Pharmicell Co Ltd
- Pharminogen Inc
- Portage Biotech Inc
- Poseida Therapeutics Inc
- Propanc Biopharma Inc
- Pyxis Oncology Inc
- Qilu Pharmaceutical Co Ltd
- Qu Biologics Inc
- Quadriga BioSciences Inc
- RemeGen Co Ltd
- Repertoire Immune Medicines Inc
- Rizen (Suzhou) Biosciences Co Ltd
- SA Science Inc
- Sanofi
- Sareum Holdings Plc
- Scancell Holdings Plc
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- ST Pharm Co Ltd
- Statera Biopharma Inc
- Suzhou Stainwei Biotech Inc
- Suzhou Zerun New Drug Research and Development Co Ltd
- TAE Life Sciences LLC
- TotalClarity Inc
- UbiVac Inc
- Unicyte AG
- Vault Pharma Inc
- Versameb AG
- Wntrix Inc
- Xbrane Biopharma AB
- Yuhan Corp
- ZielBio Inc
- Zylem Biosciences Inc
